Cancer clinical trials in the region Auvergne-Rhône-Alpes
533 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Lung cancer
#NCT06561386
#2024-513682-40-01
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
NTRK-1/2/3
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
BRAF
EGFR
ROS-1
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
13 recruiting sites
Bristol-Myers Squibb
Phase 3
Cervical / Vulvar / Vaginal cancer
#NCT07216703
#2025-521514-26-00
Required histologic types
Cervical cancer
Required histologic sub types
Squamous cell carcinoma
Adenocarcinoma
Adenosquamous carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required CPS scores
CPS Positive (>= 1)
Excluded previous treatments at localized stage
Systemic Treatment-Naive
9 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Lung cancer
#NCT06767514
#2024-518629-14-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC
Non-squamous NSCLC
Required disease stage
Metastatic
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
BRAF
EGFR
HER2
HRAS
KRAS G12C
KRAS non G12C
MET
NTRK-1/2/3
RET
ROS-1
14 recruiting sites
Summit Therapeutics
Phase 3
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT07429266
#2025-524669-25-00
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Polycythemia vera
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
Phlebotomy
Excluded previous treatments
Systemic Treatment-Naive
Targeted therapy
2 recruiting sites
Ono Pharmaceutical Co. Ltd.
Phase 3
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT06819007
#2024-516982-35-00
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Endometrioid carcinoma
Clear cell carcinoma
Mucinous carcinoma
Other epithelial ovarian cancer
Required FIGO stages
Stage III
Stage IV
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Excluded genetic anomalies
BRCA 1/2
10 recruiting sites
Daiichi Sankyo
Phase 3
Sarcoma and GIST
#NCT06127407
#2023-508507-20-00
Required histologic types
Bone sarcoma
Required histologic sub types
Chondrosarcoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
1
2
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Chemotherapy
Targeted therapy
Required sarcoma grades
Grade 1
Grade 2
Grade 3
9 recruiting sites
Phase 3
Endometrial cancer
#NCT07022483
#2024-519444-33-00
Required histologic sub types
Endometrioid adenocarcinoma
Serous adenocarcinoma
Clear cell carcinoma
Dedifferentiated and undifferentiated endometrial ...
Carcinosarcoma
Required FIGO stages
Stage II
Stage III
Required disease stage
Localized
Locally Advanced
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
POLE
6 recruiting sites
Daiichi Sankyo
Phase 3
Bladder / Urinary Tract / Urethral cancer
#NCT06319820
#2023-507684-19-00
Required histologic types
Non-invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Localized
Required genetic anomalies
FGFR
8 recruiting sites
Janssen
Phase 3
Bladder / Urinary Tract / Urethral cancer
#NCT06319820
#2023-507684-19-00
Required histologic types
Non-invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Localized
Required genetic anomalies
FGFR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
8 recruiting sites
Janssen
Phase 3
Pancreas cancer
#NCT07409272
#2025-523684-38-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required genetic anomalies
KRAS G12D
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
10 recruiting sites
Astellas Pharma Développement mondial, Inc.